10 March 2023
IXICO plc
("IXICO" or the "Company")
Contract win for a Phase 1/2 rare neurodegenerative disease gene therapy study; value c.£0.7m.
IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it has been selected by a biotech company and new client, to provide MRI imaging services for patient selection and efficacy analysis in patients with a rare form of dementia. The trial deploys an innovative gene therapy approach and is expected to last for just over four years.
Since its inception, IXICO has built an extensive portfolio of proprietary imaging data management and analysis technologies for the investigation of neurological disorders across the entire drug development lifecycle, from phase I through to commercialisation. IXICO's recently launched IXIQ.Ai platform enables the measurement of brain volumetry with increased sensitivity, compared to widely used tools.
Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be awarded this contract to support the development of this promising treatment in a rare neurodegenerative disease. It is great to see our IXIQ.Ai advanced analytics technology being chosen by new clients to support patient eligibility assessment in innovative trial designs. Deploying such approaches enables individual dosing decisions, paving the way towards personalised medicine."
For further information please contact:
| IXICO plc | +44 (0)20 3763 7499 | |
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |
| |
| |
| Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |
| Giles Balleny / Max Gould (Corporate Finance) | | |
| Michael F Johnson / Tamar Cranford-Smith (Sales) | | |
| | | |
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.